Emerging Innovations in Antithrombin Market: Unleashing the Potential to Combat Thrombotic Disorders
Market Overview:
Antithrombin is a protein found in human blood that acts as a natural blood thinner or
anticoagulant. It plays a critical role in preventing blood clotting. There are two types of
antithrombin deficiencies: type I, where there is not enough antithrombin, and type II, where
antithrombin levels are normal, but activity levels are reduced in affected patients. Symptoms of
blood clotting may include fainting, swollen limbs, increased heart rate, and shortness of breath,
among others.
According to the DataM market research report, the global antithrombin market reached US$ 545.0
million in 2022 and is projected to witness lucrative growth by reaching up to US$ 775.7 million by
2030. The global antithrombin market is expected to exhibit a CAGR of 4.6% during the forecast
period (2023-2030).
Market Drivers:
Many people all over the world suffer from a coagulation deficiency caused by high-velocity
accidents. Because of this, the use of antithrombin has increased greatly. To avoid complications
during surgery, antigen tests are conducted to measure the presence of antithrombin in the blood.
This increase in coagulation disorders has resulted in tremendous revenue for the market during the
forecast period. Modernization has led to unnecessary habits like alcoholism, which negatively
impacts liver function and the production of antithrombin.
Market Restraints:
Antithrombin deficiency is a rare genetic disorder that may go undiagnosed in many individuals. The
lack of awareness and limited diagnostic capabilities could result in underdiagnosis or delayed
treatment, thus impacting the demand for antithrombin products.
Market Opportunities:
Antithrombin products have traditionally been used in surgical and critical care settings. However,
there is potential for expansion into other therapeutic areas. Ongoing research is exploring the use
of antithrombin in conditions such as sepsis, disseminated intravascular coagulation (DIC), and liver
diseases, which could present new opportunities for the market.
For more details on this report – Request for Sample
COVID-19 Impact Analysis:
The global antithrombin market has been impacted by the COVID-19 pandemic, resulting in a
decrease in demand due to fewer surgical procedures and diagnoses of illnesses like venous
thromboembolism (VTE). Despite these challenges, the market is projected to grow in the future.
This growth can be attributed to various factors, including the increasing incidence of cardiovascular
disorders, greater awareness of the benefits of antithrombin therapy, and advancements in the
development of new antithrombin medications.
Recent Developments in the Industry:
In July 2022, Fitusiran prophylaxis showed a significant decrease in bleeding episodes
compared to previous prophylactic therapies using factor or bypassing agents in people with
hemophilia A or B, independent of the presence of inhibitors. The number of bleeds
decreased by 61% as a result of using fitusiran.
In February 2022, Novo Holdings A/S, an eminent investor in the life sciences industry,
recently announced its participation in Hemab Therapeutics' Series B Financing round, which
garnered $135 million. Hemab Therapeutics is a clinical-stage biotechnology business
focused on the discovery of novel preventative medicines for bleeding and thrombotic
diseases that presently lack appropriate treatment alternatives. Their goal is to meet the
requirements of people suffering from significant and underserved bleeding and clotting
problems.
Market Segmentation:
As per the research analysis, the global antithrombin market is segmented by usage into
therapeutics, diagnostics, research, and others; by type into anticoagulant, antiplatelet, thrombolytic
drug; by route of administration into oral, parenteral; and by source into human, recombinant goat
milk, and others.
Based on usage, the therapeutics segment is projected to dominate the global antithrombin
market, accounting market share of about 52.3%, owing to the rising occurrence of disorders
linked with antithrombin deficiency, such as deep vein thrombosis (DVT), pulmonary
embolism (PE), and disseminated intravascular coagulation (DIC) and also due to sepsis
inflammation. In addition, the rising awareness about the benefits of antithrombin therapy
is also expected to drive the growth of this segment.
Moreover, the development of new antithrombin therapies and commercialization by
market players through collaboration and partnerships will help to drive the antithrombin
market share for the therapeutic segment. For instance, in February 2022, Grifols, a leading
producer of plasma-based pharmaceuticals, partnered with Endpoint Health, a precision
medicine business, focusing on solving critical care requirements connected to the immune
system. This collaboration intends to develop and commercialize an antithrombin III (AT-III)
medication for sepsis. Thus, owing to the above factors, the market segment is expected to
hold the largest market share over the forecast period.
Geographical Classification:
The global antithrombin market is segmented into North America, Europe, South America, Asia
Pacific, and Middle East & Africa.
Asia-Pacific Antithrombin Market:
Asia-Pacific is expected to witness the largest market share during the factor in terms of global
revenue contribution. Factors responsible for the dominant position in the market can be credited to
the emerging economies in the region, China & India. Furthermore, the prevalence of venous
thromboembolism (VTE) in the Asian population is expected to occur at a much lower rate than the
Western counterparts.
Growing patient awareness and increased consumer spending on healthcare facilities will further
boost the growth of the market during the forecast timeframe.
North America Antithrombin Market:
In terms of revenue contribution, the North American market dominates the global antithrombin
market in comparison to markets in other regions. This is due to the rising number of antithrombin
approvals in the region.
Competitive Landscape:
The major global players in the market include CSL Limited, Grifols SA, Takeda Pharmaceuticals,
Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions
Inc., BDI Pharma, and among others.
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regard to the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
The report offers a comprehensive evaluation of the market in terms of market
value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights,
historical data (2021-2022) and verifiable projections about market size during the
forecast period (2023-2030).
Visualize the composition of the global antithrombin market by usage, type, route of
administration, source, and region, highlighting the key commercial assets and
players.
o By Usage: Therapeutics, Diagnostics, Research, Others
o By Type: Anticoagulant, Antiplatelet, Thrombolytic Drug
o By Route of Administration: Oral, Parenteral
o By Source: Human, Recombinant Goat Milk, Others
o By Region: North America, South America, Europe, Asia Pacific, Middle East & Africa
Identify commercial opportunities in the global antithrombin market by analyzing trends
and co-development deals.
The report also covers data insights on various industry forces such as Porter’s five
forces analysis, supply chain analysis, pricing analysis, regulatory analysis.
Excel data sheet with thousands of data points of global antithrombin market-level 4/5
segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive
qualitative interviews and in-depth market study.
Product mapping in Excel for the key product of all major market players
The report will provide access to approximately 61 market data tables, 64 figures and
close to 180 pages.
About Us:
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business
solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top
trademark trends, insights and developments to emancipate swift and astute solutions to clients like
you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of
6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+
countries; catering to the key business research needs that influence the growth trajectory of our
vast clientele.
